Celanese Corporation.（NYSE: CE), a global technology and specialty materials company, today announced the launch of VitalDose™, an ethylene vinyl acetate (EVA) polymer-based excipient that facilitates drug makers’ efforts to develop and commercialize controlled-release pharmaceutical solutions.
VitalDose赋形剂基于EVA聚合物，在透皮，皮下植入物和粘膜插入剂型的设计中提供广泛的灵活性。VitalDose提供可定制的释放属性以及用于在制药产品线扩展和新概念开发中使用的新送货路线的可能性。
“通过应用Celanese的VitalDose Eva辅助技术，我们正在帮助我们的客户在充满复杂挑战的竞争市场中保留优势，”Celanese的EVA绩效聚合物商业总经理Mark Murray Mark Murray说。“随着竞争，特别是泛型，在制药行业的上升，发展创新剂型现在是保留行业中竞争优势的关键。默里说，开发现有产品的新开发尚未溶解的药物的生物利用度，或提高新开发的尚未溶解的药物的生物利用度，是制药公司认为策略的重要选择，“默里说。
“Celanese is investing in new and innovative resources to grow with the evolving pharmaceutical industry and is maximizing the value of that investment by building on its exceptional excipient technology with product development support and regulatory expertise to meet its customers’ specialized needs,” said Jon Mortimer, chief technology officer, Celanese Office of Strategic Growth. “VitalDose offers a wide degree of flexibility in the design of controlled release dosage solutions and is another example of how Celanese is committed to helping companies realize innovative growth opportunities through advanced product development.”
来源：http://www.celanese.com/